       Document 0567
 DOCN  M9630567
 TI    Role of intralesional vinblastine administration in treatment of
       intraoral Kaposi's sarcoma in AIDS.
 DT    9603
 AU    Flaitz CM; Nichols CM; Hicks MJ; Department of Stomatology, University
       of Texas-Houston Health; Science Center, USA.
 SO    Eur J Cancer B Oral Oncol. 1995 Jul;31B(4):280-5. Unique Identifier :
       AIDSLINE MED/96103639
 AB    The purpose of this clinical study was to determine the effect of
       intralesional vinblastine administration on intraoral Kaposi's sarcoma
       (KS) in AIDS patients. One hundred and forty-four KS lesions in 50
       HIV-positive homosexual males (mean CD4 count 64/mm3) were treated
       periodically with intralesional vinblastine injection (0.1 mg/cm2) until
       lesion resolution or no further reduction in lesional area. The most
       common lesion sites were: palate 56% (hard palate 42%, soft palate 14%);
       gingiva 22% (maxillary 15%, mandibular 7%); and maxillary tuberosity 6%.
       The mean lesion area was 4.6 cm2 (range = 0.1-35 cm2). Complete
       resolution occurred in 74%. The mean reduction in lesional area was 93%
       for all lesions. Lesions with only a partial response (26%) to
       vinblastine had a mean reduction in the lesional area of 69%. The mean
       number of treatments was 2.4 (range = 1-6). The recurrence rate was 26%
       with a mean disease-free period of 12.9 weeks. Recurrence rates were
       highest for nodular (40%) and purple macular lesions with focal
       nodularity (36%). The most frequent complications were transient pain
       (72%), superficial mucosal ulceration (22%) and transient paresthesia
       (12%). Intralesional vinblastine administration produced complete
       resolution in a substantial number of intraoral KS lesions and
       represents a well-tolerated treatment regimen for localised control of
       intraoral KS lesions. Owing to a 25% recurrence rate, re-evaluation is
       necessary for treatment of recurrent and new Kaposi's sarcoma lesions.
 DE    Acquired Immunodeficiency Syndrome/*COMPLICATIONS  Adult  Antineoplastic
       Agents, Phytogenic/*ADMINISTRATION & DOSAGE/  ADVERSE EFFECTS  Human
       Injections, Intralesional  Male  Middle Age  Mouth Neoplasms/*DRUG
       THERAPY/PATHOLOGY/VIROLOGY  Neoplasm Recurrence, Local  Sarcoma,
       Kaposi's/*DRUG THERAPY/PATHOLOGY/VIROLOGY  Vinblastine/*ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS  CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

